BioMarin Pharmaceutical Inc. (BMRN) Market Cap & Valuation Ratios
BioMarin Pharmaceutical Inc. (BMRN) has a market cap of $10.8B, a trailing P/E of 151.2 and a price-to-sales ratio of 3.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BMRNBioMarin Pharmaceutical Inc.Follow BMRN — free
—
Price chart with a free account
- Market cap
- 10.8B
- P/E TTM
- 151.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 9 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| BMRN | 11 | 151.2 | 4.2 | 46.8 | 6.8% | +11% | 4% | 1.0% |
| BBIO | 13 | — | 21.3 | — | -3.2% | +202% | -70% | — |
| SMMT | 12 | — | — | — | -3.7% | — | — | -513% |
| TECH | 11 | 63.1 | 9.3 | 32.4 | 2.3% | -0.4% | 21% | 9% |
| MDGL | 10 | — | 7.4 | — | -2.1% | +149% | -25% | -54% |
| CORT | 9.3 | 204.4 | 10.8 | 1110.0 | 1.2% | +16% | 0.8% | 0.9% |
| KRYS | 9.2 | 39.0 | 19.0 | 41.1 | 2.8% | +23% | 45% | 19% |
| KYMR | 9.2 | — | 81.1 | — | -2.6% | +135% | -334% | -35% |
| CAI | 9.0 | 85.6 | 8.7 | 49.7 | 1.4% | +85% | 15% | 61% |
| PCVX | 9.0 | — | — | — | -10.2% | — | — | -44% |
| PTGX | 9.0 | 135.7 | 29.0 | 136.5 | 1.5% | +35% | 21% | 12% |
| Median of these 10 | 85.6 | 14.9 | 49.7 | -0.5% | +60% | 8% | 0.9% |
P/E 151.2 vs. a peer median of 85.6; EV/Sales 4.2 vs. 14.9. BMRN's own P/E sits at the 64th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesBBIO and SMMT and MDGL and KYMR and PCVX have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
BioMarin Pharmaceutical Inc. — questions
- What is BioMarin Pharmaceutical Inc.'s market cap?
- $10.8B.
- What is BioMarin Pharmaceutical Inc.'s P/E ratio?
- 151.2 on trailing twelve-month earnings to 2026-06-30.
- What is BioMarin Pharmaceutical Inc.'s price-to-sales ratio?
- 3.2.
Every figure on this page comes from BioMarin Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.